Informed Consent Guidance Focuses On Children And Non-English Speaking Subjects
This article was originally published in The Pink Sheet Daily
FDA’s draft guidance urges consideration of ethical ramifications of enrolling or excluding potential subjects from clinical trials when there may be a language barrier.
You may also be interested in...
Novartis co-leads industry forum on preapproval access that aims to share best practices and engage patient groups; Janssen is launching three pilots to leverage collection of preapproval access data.
FDA is worried about drug names that could appear to overstate efficacy and impact consumer and healthcare provider perceptions of the product.